[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Research Letter
October 4, 2016

Safety of a Hybrid Closed-Loop Insulin Delivery System in Patients With Type 1 Diabetes

Author Affiliations
  • 1International Diabetes Center, Minneapolis, Minnesota
  • 2Barbara Davis Center for Diabetes, University of Colorado Denver, Aurora
  • 3Yale University, New Haven, Connecticut
  • 4Stanford University, Stanford, California
  • 5Atlanta Diabetes Associates, Atlanta, Georgia
  • 6Medtronic, Northridge, California
JAMA. 2016;316(13):1407-1408. doi:10.1001/jama.2016.11708

Closed-loop artificial pancreas technology uses a control algorithm to automatically adjust insulin delivery based on subcutaneous sensor data to improve diabetes management. Currently available systems stop insulin in response to existing1 or predicted2 low sensor glucose values, whereas hybrid closed-loop systems combine user-delivered premeal boluses with automatic interprandial insulin delivery.3 This study investigated the safety of a hybrid closed-loop system in patients with type 1 diabetes.

First Page Preview View Large
First page PDF preview
First page PDF preview